Skip to main content

PLIANT THERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

PLRX$0.79-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits and Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules.

(a)The following documents are filed as part of this Annual Report:

  1. Financial Statements. See Index to Financial Statements in Part II Item 8 of this Annual Report on Form 10-K.

  2. Financial Statement Schedules. None. All financial statement schedules are omitted because they are not applicable, not required under the instructions, or the requested information is included in the financial statements or notes thereto.

  3. Exhibits. The following is a list of exhibits filed with this Annual Report or incorporated herein by reference:

Incorporated by Reference
ExhibitNumber · Exhibit Description · Form · File No. · Exhibit · FilingDate · FileHerewith
3.1Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.10-Q001-393033.1August 11, 2020
3.2Second Amended and Restated Bylaws of the Registrant, as currently in effect.8-K001-393033.1September 16, 2022
4.1Specimen Common Stock Certificate of the Registrant.S-1/A333-2381464.1May 26, 2020
4.2Description of the Registrant’s Securities10-K001-393034.3March 16, 2021
10.1#2020 Stock Option and Incentive Plan and forms of award agreement.S-1/A333-23814610.2May 26, 2020
10.2#2015 Equity Incentive Plan and forms of award agreements thereunder.S-1333-23814610.1May 11, 2020
10.3#2020 Employee Stock Purchase Plan.S-1/A333-23814610.3May 26, 2020
10.4#Senior Executive Cash Incentive Bonus Plan.S-1333-23814610.4May 11, 2020
10.5#Non-Employee Director Compensation Policy.S-1/A333-23814610.6May 26, 2020
10.6#Executive Severance Plan.S-1333-23814610.7May 11, 2020
10.7#Offer Letter, by and between the Registrant and Mike Ouimette, dated August 17, 2020.10-Q001-3930310.1November 10. 2020
10.8#Offer Letter, by and between the Registrant and Éric Lefebvre, M.D., dated February 28, 2018.S-1333-23814610.11May 11, 2020
10.9#Offer Letter, by and between the Registrant and Keith Cummings, M.D., MBA, dated November 29, 2018.S-1333-23814610.10May 11, 2020
10.10#Offer Letter, by and between the Registrant and Hans Hull, J.D., dated February 10, 2016.S-1333-23814610.9May 11, 2020
10.11#Offer Letter, by and between the Registrant and Bernard Coulie, M.D., Ph.D., dated October 12, 2015.S-1333-23814610.8May 11, 2020
10.12#Form of Indemnification Agreement, by and between the Registrant and each of its directors and certain officers.S-1333-23814610.13May 11, 2020
10.13Office Lease, by and between the Registrant and 260 Littlefield Avenue South San Francisco, California 94080, dated February 6, 2018.S-1333-23814610.14May 11, 2020
10.14#2022 Inducement Plan dated September 14, 2022.10-K001-3930310.17March 9, 2023
Incorporated by Reference
ExhibitNumberExhibit DescriptionFormFile No.ExhibitFilingDateFileHerewith
10.15Loan and Security Agreement, by and between Registrant and Oxford Finance LLC, dated May 4, 2022.8-K001-3930310.1May 5, 2022
10.16First Amendment to Loan and Security Agreement, by and between Registrant and Oxford Finance LLC, dated October 4, 2022.10-K001-3930310.17March 9, 2023
10.17#Amended and Restated Non-Employee Director Compensation PolicyX
10.18#Offer Letter, by and between the Registrant and Lily Cheung, dated December 21, 2022.10-K001-3930310.21March 9, 2023
10.19#Lease Agreement by and between the Registrant and HCP BTC, LLC, dated September 28, 2023.8-K001-3930310.1October 23, 2023
10.20#Termination Agreement by and between the Registrant and Healthpeak OP, LLC, dated September 28, 2023.8-K001-3930310.2October 23, 2023
23.1Consent of Independent Registered Public Accounting FirmX
31.1Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
31.2Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
32.1**Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
97Clawback PolicyX
101.INSXBRL Instance DocumentX
101.SCHXBRL Taxonomy Extension Schema DocumentX
101.CALXBRL Taxonomy Calculation Linkbase DocumentX
101.DEFXBRL Taxonomy Extension Definition DocumentX
101.LABXBRL Taxonomy Label Linkbase DocumentX
101.PREXBRL Taxonomy Presentation Linkbase DocumentX

** The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Annual Report on Form 10-K and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.